Press Releases

Date Title and Summary View
Toggle Summary Oxford Immunotec releases the T-SPOT® Discovery™ SARS-CoV-2 kit for research into measuring the T cell immune response to SARS-CoV-2, which may offer new insights into immunity to COVID-19
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces the release of the T-SPOT Discovery SARS-CoV-2 test kit.
View HTML
Toggle Summary Oxford Immunotec Reports First Quarter 2020 Financial Results
First quarter revenue of $13.9 million, a decrease of 6% compared to prior year period, due to the impact of COVID-19 in China Gross margins expanded 270bps to 74% Ended the quarter with $166 million of cash and cash equivalents OXFORD, United Kingdom and MARLBOROUGH, Mass., May 05, 2020 (GLOBE
View HTML
Toggle Summary Oxford Immunotec Schedules First Quarter 2020 Earnings Release and Conference Call for May 5, 2020
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2020 financial results before the open of the market on
View HTML
Toggle Summary Oxford Immunotec announces successful re-registration of the T-SPOT®.TB test in China
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that it has successfully obtained re-registration of the T-SPOT. TB test in China.
View HTML
Toggle Summary Oxford Immunotec Reports Fourth Quarter and Full Year 2019 Financial Results
Fourth quarter 2019 revenue of $18.1 million, an increase of 18% compared to the prior year period Fourth quarter 2019 gross margin of 78.3%, an increase of 410 basis points from the prior year period Fourth quarter 2019 net loss of $1.6 million, as compared to a pro forma (see tables below) net
View HTML
Toggle Summary Oxford Immunotec to Present at the Cowen and Company 40th Annual Health Care Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the Cowen and Company 40 th Annual Health
View HTML
Toggle Summary Oxford Immunotec Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for March 2, 2020
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release fourth quarter and full year 2019 financial results before the open of the
View HTML
Toggle Summary Oxford Immunotec Announces New Data on the Utility of T-SPOT®.CMV in Kidney and Stem Cell Transplant
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announces two ground-breaking publications in Clinical Infectious Diseases (CID) on the performance of T-SPOT.
View HTML
Toggle Summary Oxford Immunotec Announces Donation in Support of Coronavirus Testing Efforts to Help Differentiate Tuberculosis from the COVID-19
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announced they are planning a new initiative to commemorate the coming World Tuberculosis Day, bring the
View HTML
Toggle Summary Oxford Immunotec to Present at the 38th Annual J.P. Morgan Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the 38th Annual J.P.
View HTML